;PMID: 2351103
;source_file_948.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..194] = [t:44..194]
;2)section:[e:198..238] = [t:198..238]
;3)section:[e:242..342] = [t:242..342]
;4)sentence:[e:346..634] = [t:346..634]
;5)sentence:[e:635..841] = [t:635..841]
;6)sentence:[e:842..936] = [t:842..936]
;7)sentence:[e:937..1089] = [t:937..1089]
;8)sentence:[e:1090..1367] = [t:1090..1367]
;9)sentence:[e:1368..1473] = [t:1368..1473]
;10)sentence:[e:1474..1606] = [t:1474..1606]
;11)sentence:[e:1607..1822] = [t:1607..1822]
;12)sentence:[e:1823..2021] = [t:1823..2021]
;13)sentence:[e:2022..2301] = [t:2022..2301]
;14)sentence:[e:2302..2572] = [t:2302..2572]
;15)sentence:[e:2573..2672] = [t:2573..2672]
;16)sentence:[e:2673..2913] = [t:2673..2913]
;17)sentence:[e:2914..3110] = [t:2914..3110]
;18)section:[e:3110..3143] = [t:3110..3143]
;19)section:[e:3147..3191] = [t:3147..3191]

;section 0 Span:0..38
;Endocrinology. 1990 Jun;126(6):2910-8.
(SEC
  (FRAG (NNP:[0..13] Endocrinology) (,:[13..14] .) (CD:[15..19] 1990)
        (CC:[20..28] Jun;126-LRB-) (CD:[28..30] 6-RRB-) (CD:[30..35] :2910)
        (::[35..36] -) (CD:[36..38] 8.)))

;sentence 1 Span:44..194
;Mechanism for control of hydroxymethylglutaryl-coenzyme A reductase and 
;cytochrome P-450 side chain cleavage message and enzyme in the corpus
;luteum.
;[69..111]:substance:"hydroxymethylglutaryl-coenzyme A reductase"
;[117..153]:cyp450:"cytochrome P-450 side chain cleavage"
;[166..172]:substance:"enzyme"
(SENT
  (NP-HLN
    (NP (NN:[44..53] Mechanism))
    (PP (IN:[54..57] for)
      (NP
        (NP (NN:[58..65] control))
        (PP (IN:[66..68] of)
          (NP
            (NP
              (NML (NN:[69..90] hydroxymethylglutaryl) (HYPH:[90..91] -)
                   (NN:[91..99] coenzyme) (NN:[100..101] A))
              (NN:[102..111] reductase))
            (CC:[112..115] and)
            (NP
              (NP
                (NML-1 (NN:[117..127] cytochrome) (NN:[128..133] P-450)
                  (NML (NN:[134..138] side) (NN:[139..144] chain))
                  (NN:[145..153] cleavage))
                (NN:[154..161] message))
              (CC:[162..165] and)
              (NP
                (NML-1 (-NONE-:[165..165] *P*))
                (NN:[166..172] enzyme)))))
        (PP-LOC (IN:[173..175] in)
          (NP (DT:[176..179] the) (NN:[180..186] corpus) (NN:[187..193] luteum)))))
    (.:[193..194] .)))

;section 2 Span:198..238
;Puryear TK, McLean MP, Khan I, Gibori G.
(SEC
  (FRAG (NNP:[198..205] Puryear) (NNP:[206..208] TK) (,:[208..209] ,)
        (NNP:[210..216] McLean) (NN:[217..219] MP) (,:[219..220] ,)
        (NNP:[221..225] Khan) (NNP:[226..227] I) (,:[227..228] ,)
        (NNP:[229..235] Gibori) (NNP:[236..238] G.)))

;section 3 Span:242..342
;Department of Physiology and Biophysics, University of Illinois College of 
;Medicine, Chicago 60612.
(SEC
  (FRAG (NNP:[242..252] Department) (IN:[253..255] of)
        (NNP:[256..266] Physiology) (CC:[267..270] and)
        (NNP:[271..281] Biophysics) (,:[281..282] ,) (NNP:[283..293] University)
        (IN:[294..296] of) (NNP:[297..305] Illinois) (NNP:[306..313] College)
        (IN:[314..316] of) (NNP:[318..326] Medicine) (,:[326..327] ,)
        (NNP:[328..335] Chicago) (CD:[336..341] 60612) (.:[341..342] .)))

;sentence 4 Span:346..634
;The present study was undertaken to investigate the mechanism for control of 
;hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and cytochrome P-450
;side  chain cleavage (P-450scc), enzymes involved in the synthesis and
;processing of  cholesterol in the corpus luteum of pregnant rats.
;[424..476]:substance:"hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase"
;[481..518]:cyp450:"cytochrome P-450 side  chain cleavage"
;[520..528]:cyp450:"P-450scc"
;[531..538]:substance:"enzymes"
;[584..595]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ-1 (DT:[346..349] The) (JJ:[350..357] present) (NN:[358..363] study))
    (VP (VBD:[364..367] was)
      (VP (VBN:[368..378] undertaken)
        (NP-1 (-NONE-:[378..378] *))
        (S-PRP
          (NP-SBJ (-NONE-:[378..378] *))
          (VP (TO:[379..381] to)
            (VP (VB:[382..393] investigate)
              (NP
                (NP (DT:[394..397] the) (NN:[398..407] mechanism))
                (PP (IN:[408..411] for)
                  (NP
                    (NP (NN:[412..419] control))
                    (PP (IN:[420..422] of)
                      (NP
                        (NP
                          (NP
                            (NML
                              (NML (NN:[424..445] hydroxymethylglutaryl)
                                   (HYPH:[445..446] -) (NN:[446..454] coenzyme)
                                   (NN:[455..456] A))
                              (NML (-LRB-:[457..458] -LRB-)
                                   (NN:[458..465] HMG-CoA)
                                   (-RRB-:[465..466] -RRB-)))
                            (NN:[467..476] reductase))
                          (CC:[477..480] and)
                          (NP
                            (NP
                              (NML
                                (NML (NN:[481..491] cytochrome)
                                     (NN:[492..497] P-450))
                                (NN:[498..502] side) (NN:[504..509] chain))
                              (NN:[510..518] cleavage))
                            (NP (-LRB-:[519..520] -LRB-)
                                (NN:[520..528] P-450scc)
                                (-RRB-:[528..529] -RRB-))))
                        (,:[529..530] ,)
                        (NP
                          (NP (NNS:[531..538] enzymes))
                          (VP (VBN:[539..547] involved)
                            (NP (-NONE-:[547..547] *))
                            (PP-CLR (IN:[548..550] in)
                              (NP
                                (NP
                                  (NP (DT:[551..554] the)
                                      (NN:[555..564] synthesis))
                                  (CC:[565..568] and)
                                  (NP (NN:[569..579] processing)))
                                (PP (IN:[580..582] of)
                                  (NP (NN:[584..595] cholesterol)))
                                (PP-LOC (IN:[596..598] in)
                                  (NP
                                    (NP (DT:[599..602] the)
                                        (NN:[603..609] corpus)
                                        (NN:[610..616] luteum))
                                    (PP (IN:[617..619] of)
                                      (NP (JJ:[620..628] pregnant)
                                          (NNS:[629..633] rats)))))))))))))))))))
    (.:[633..634] .)))

;sentence 5 Span:635..841
;The role of sterol and  estradiol were investigated by administering
;4-aminopyrazolo-[3,4d]pyrimidine  (4-APP), aminoglutethimide and/or estradiol
;to day 12  hypophysectomized-hysterectomized pregnant rats.
;[647..653]:substance:"sterol"
;[659..668]:substance:"estradiol"
;[704..736]:substance:"4-aminopyrazolo-[3,4d]pyrimidine"
;[739..744]:substance:"4-APP"
;[747..764]:substance:"aminoglutethimide"
;[772..781]:substance:"estradiol"
;[785..788]:quantitative-units:"day"
;[789..791]:quantitative-value:"12"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[635..638] The) (NN:[639..643] role))
      (PP (IN:[644..646] of)
        (NP (NN:[647..653] sterol) (CC:[654..657] and) (NN:[659..668] estradiol))))
    (VP (VBD:[669..673] were)
      (VP (VBN:[674..686] investigated)
        (NP-1 (-NONE-:[686..686] *))
        (PP-MNR (IN:[687..689] by)
          (S-NOM
            (NP-SBJ (-NONE-:[689..689] *))
            (VP (VBG:[690..703] administering)
              (NP
                (NP
                  (NP (NN:[704..736] 4-aminopyrazolo--LSB-3,4d-RSB-pyrimidine))
                  (NP (-LRB-:[738..739] -LRB-) (NN:[739..744] 4-APP)
                      (-RRB-:[744..745] -RRB-)))
                (,:[745..746] ,)
                (NP (NN:[747..764] aminoglutethimide))
                (CC:[765..771] and/or)
                (NP (NN:[772..781] estradiol)))
              (PP-CLR (TO:[782..784] to)
                (NP
                  (NML (NN:[785..788] day) (CD:[789..791] 12))
                  (ADJP (VBN:[793..810] hypophysectomized) (HYPH:[810..811] -)
                        (VBN:[811..826] hysterectomized))
                  (JJ:[827..835] pregnant) (NNS:[836..840] rats))))))))
    (.:[840..841] .)))

;sentence 6 Span:842..936
;Estradiol treatment markedly  increased mRNA levels of HMG-CoA reductase in
;the corpus luteum.
;[842..851]:substance:"Estradiol"
;[882..886]:substance:"mRNA"
;[897..914]:substance:"HMG-CoA reductase"
(SENT
  (S
    (NP-SBJ (NN:[842..851] Estradiol) (NN:[852..861] treatment))
    (ADVP (RB:[862..870] markedly))
    (VP (VBD:[872..881] increased)
      (NP
        (NP (NN:[882..886] mRNA) (NNS:[887..893] levels))
        (PP (IN:[894..896] of)
          (NP (NN:[897..904] HMG-CoA) (NN:[905..914] reductase))))
      (PP-LOC (IN:[915..917] in)
        (NP (DT:[918..921] the) (NN:[922..928] corpus) (NN:[929..935] luteum))))
    (.:[935..936] .)))

;sentence 7 Span:937..1089
;This  stimulatory effect of estradiol was specific for the reductase since
;the mRNA  for luteal P-450scc did not increase following estradiol
;treatment.
;[965..974]:substance:"estradiol"
;[996..1005]:substance:"reductase"
;[1016..1020]:substance:"mRNA"
;[1033..1041]:cyp450:"P-450scc"
;[1069..1078]:substance:"estradiol"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[937..941] This) (JJ:[943..954] stimulatory)
          (NN:[955..961] effect))
      (PP (IN:[962..964] of)
        (NP (NN:[965..974] estradiol))))
    (VP (VBD:[975..978] was)
      (ADJP-PRD (JJ:[979..987] specific)
        (PP (IN:[988..991] for)
          (NP (DT:[992..995] the) (NN:[996..1005] reductase))))
      (SBAR-ADV (IN:[1006..1011] since)
        (S
          (NP-SBJ
            (NP (DT:[1012..1015] the) (NN:[1016..1020] mRNA))
            (PP (IN:[1022..1025] for)
              (NP (JJ:[1026..1032] luteal) (NN:[1033..1041] P-450scc))))
          (VP (VBD:[1042..1045] did) (RB:[1046..1049] not)
            (VP (VB:[1050..1058] increase)
              (PP-TMP (VBG:[1059..1068] following)
                (NP (NN:[1069..1078] estradiol) (NN:[1079..1088] treatment))))))))
    (.:[1088..1089] .)))

;sentence 8 Span:1090..1367
;To determine  whether estradiol's action on HMG-CoA reductase mRNA was
;mediated by changes in  cellular free cholesterol, the separate and combined
;action of estradiol and  either 4-APP or aminoglutethimide on both sterol
;content and HMG-CoA reductase  expression was examined.
;[1112..1121]:substance:"estradiol"
;[1134..1156]:substance:"HMG-CoA reductase mRNA"
;[1199..1210]:substance:"cholesterol"
;[1248..1257]:substance:"estradiol"
;[1270..1275]:substance:"4-APP"
;[1279..1296]:substance:"aminoglutethimide"
;[1305..1311]:substance:"sterol"
;[1324..1341]:substance:"HMG-CoA reductase"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1090..1090] *))
      (VP (TO:[1090..1092] To)
        (VP (VB:[1093..1102] determine)
          (SBAR (IN:[1104..1111] whether)
            (S
              (NP-SBJ-1
                (NP
                  (NP (NN:[1112..1121] estradiol) (POS:[1121..1123] 's))
                  (NN:[1124..1130] action))
                (PP (IN:[1131..1133] on)
                  (NP
                    (NML (NN:[1134..1141] HMG-CoA) (NN:[1142..1151] reductase))
                    (NN:[1152..1156] mRNA))))
              (VP (VBD:[1157..1160] was)
                (VP (VBN:[1161..1169] mediated)
                  (NP-1 (-NONE-:[1169..1169] *))
                  (PP (IN:[1170..1172] by)
                    (NP-LGS
                      (NP (NNS:[1173..1180] changes))
                      (PP (IN:[1181..1183] in)
                        (NP (JJ:[1185..1193] cellular) (JJ:[1194..1198] free)
                            (NN:[1199..1210] cholesterol))))))))))))
    (,:[1210..1211] ,)
    (NP-SBJ-3
      (NP (DT:[1212..1215] the)
        (NML
          (NML (JJ:[1216..1224] separate)
            (NML-2 (-NONE-:[1224..1224] *P*)))
          (CC:[1225..1228] and)
          (NML (VBN:[1229..1237] combined)
            (NML-2 (NN:[1238..1244] action)))))
      (PP (IN:[1245..1247] of)
        (NP
          (NP (NN:[1248..1257] estradiol))
          (CC:[1258..1261] and)
          (NP (CC:[1263..1269] either)
            (NP (NN:[1270..1275] 4-APP))
            (CC:[1276..1278] or)
            (NP (NN:[1279..1296] aminoglutethimide)))))
      (PP (IN:[1297..1299] on)
        (NP (CC:[1300..1304] both)
          (NP (NN:[1305..1311] sterol) (NN:[1312..1319] content))
          (CC:[1320..1323] and)
          (NP
             (NN:[1324..1331] HMG-CoA) (NN:[1332..1341] reductase)
            (NN:[1343..1353] expression)))))
    (VP (VBD:[1354..1357] was)
      (VP (VBN:[1358..1366] examined)
        (NP-3 (-NONE-:[1366..1366] *))))
    (.:[1366..1367] .)))

;sentence 9 Span:1368..1473
;The estradiol induced rise in HMG-CoA reductase was not  accompanied by a
;decrease in luteal cholesterol.
;[1372..1381]:substance:"estradiol"
;[1398..1415]:substance:"HMG-CoA reductase"
;[1461..1472]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1368..1371] The)
        (ADJP (NN:[1372..1381] estradiol) (VBN:[1382..1389] induced))
        (NN:[1390..1394] rise))
      (PP (IN:[1395..1397] in)
        (NP (NN:[1398..1405] HMG-CoA) (NN:[1406..1415] reductase))))
    (VP (VBD:[1416..1419] was) (RB:[1420..1423] not)
      (VP (VBN:[1425..1436] accompanied)
        (NP-1 (-NONE-:[1436..1436] *))
        (PP (IN:[1437..1439] by)
          (NP-LGS
            (NP (DT:[1440..1441] a) (NN:[1442..1450] decrease))
            (PP (IN:[1451..1453] in)
              (NP (JJ:[1454..1460] luteal) (NN:[1461..1472] cholesterol)))))))
    (.:[1472..1473] .)))

;sentence 10 Span:1474..1606
;4-APP treatment depleted  cholesterol in the corpus luteum and induced a
;greater increase in HMG-CoA  reductase mRNA than estradiol.
;[1474..1479]:substance:"4-APP"
;[1500..1511]:substance:"cholesterol"
;[1567..1590]:substance:"HMG-CoA  reductase mRNA"
;[1596..1605]:substance:"estradiol"
(SENT
  (S
    (NP-SBJ (NN:[1474..1479] 4-APP) (NN:[1480..1489] treatment))
    (VP
      (VP (VBD:[1490..1498] depleted)
        (NP (NN:[1500..1511] cholesterol))
        (PP-LOC (IN:[1512..1514] in)
          (NP (DT:[1515..1518] the) (NN:[1519..1525] corpus)
              (NN:[1526..1532] luteum))))
      (CC:[1533..1536] and)
      (VP (VBD:[1537..1544] induced)
        (NP
          (NP (DT:[1545..1546] a) (JJR:[1547..1554] greater)
              (NN:[1555..1563] increase))
          (PP (IN:[1564..1566] in)
            (NP
              (NML (NN:[1567..1574] HMG-CoA) (NN:[1576..1585] reductase))
              (NN:[1586..1590] mRNA)))
          (PP (IN:[1591..1595] than)
            (NP (NN:[1596..1605] estradiol))))))
    (.:[1605..1606] .)))

;sentence 11 Span:1607..1822
;Combined treatment with estradiol and 4-APP  resulted in a synergistic
;increase in HMG-CoA reductase mRNA despite the fact  that estradiol did not
;further reduce the 4-APP induced decrease in luteal  sterol content.
;[1631..1640]:substance:"estradiol"
;[1645..1650]:substance:"4-APP"
;[1690..1712]:substance:"HMG-CoA reductase mRNA"
;[1736..1745]:substance:"estradiol"
;[1773..1778]:substance:"4-APP"
;[1807..1813]:substance:"sterol"
(SENT
  (S
    (NP-SBJ
      (NP (VBN:[1607..1615] Combined) (NN:[1616..1625] treatment))
      (PP (IN:[1626..1630] with)
        (NP (NN:[1631..1640] estradiol) (CC:[1641..1644] and)
            (NN:[1645..1650] 4-APP))))
    (VP (VBD:[1652..1660] resulted)
      (PP-CLR (IN:[1661..1663] in)
        (NP
          (NP (DT:[1664..1665] a) (JJ:[1666..1677] synergistic)
              (NN:[1678..1686] increase))
          (PP (IN:[1687..1689] in)
            (NP
              (NML (NN:[1690..1697] HMG-CoA) (NN:[1698..1707] reductase))
              (NN:[1708..1712] mRNA)))))
      (PP (IN:[1713..1720] despite)
        (NP (DT:[1721..1724] the) (NN:[1725..1729] fact)
          (SBAR (IN:[1731..1735] that)
            (S
              (NP-SBJ (NN:[1736..1745] estradiol))
              (VP (VBD:[1746..1749] did) (RB:[1750..1753] not)
                (ADVP (RB:[1754..1761] further))
                (VP (VB:[1762..1768] reduce)
                  (NP
                    (NP (DT:[1769..1772] the)
                      (ADJP (NN:[1773..1778] 4-APP) (VBN:[1779..1786] induced))
                      (NN:[1787..1795] decrease))
                    (PP (IN:[1796..1798] in)
                      (NP
                        (NML (JJ:[1799..1805] luteal) (NN:[1807..1813] sterol))
                        (NN:[1814..1821] content)))))))))))
    (.:[1821..1822] .)))

;sentence 12 Span:1823..2021
;This indicates that luteal cells possess an estradiol-mediated  mechanism for
;up-regulation of HMG-CoA reductase gene expression which is  distinct from
;the cholesterol negative feedback regulation.
;[1867..1876]:substance:"estradiol"
;[1918..1935]:substance:"HMG-CoA reductase"
;[1980..1991]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ (DT:[1823..1827] This))
    (VP (VBZ:[1828..1837] indicates)
      (SBAR (IN:[1838..1842] that)
        (S
          (NP-SBJ (JJ:[1843..1849] luteal) (NNS:[1850..1855] cells))
          (VP (VBP:[1856..1863] possess)
            (NP
              (NP
                (NP (DT:[1864..1866] an)
                  (ADJP (NN:[1867..1876] estradiol) (HYPH:[1876..1877] -)
                        (VBN:[1877..1885] mediated))
                  (NN:[1887..1896] mechanism))
                (PP (IN:[1897..1900] for)
                  (NP
                    (NP (RP:[1901..1903] up) (HYPH:[1903..1904] -)
                        (NN:[1904..1914] regulation))
                    (PP (IN:[1915..1917] of)
                      (NP
                        (NML (NN:[1918..1925] HMG-CoA)
                             (NN:[1926..1935] reductase))
                        (NN:[1936..1940] gene) (NN:[1941..1951] expression))))))
              (SBAR
                (WHNP-1 (WDT:[1952..1957] which))
                (S
                  (NP-SBJ-1 (-NONE-:[1957..1957] *T*))
                  (VP (VBZ:[1958..1960] is)
                    (ADJP-PRD (JJ:[1962..1970] distinct)
                      (PP (IN:[1971..1975] from)
                        (NP (DT:[1976..1979] the) (NN:[1980..1991] cholesterol)
                          (NML (JJ:[1992..2000] negative)
                               (NN:[2001..2009] feedback))
                          (NN:[2010..2020] regulation))))))))))))
    (.:[2020..2021] .)))

;sentence 13 Span:2022..2301
;However, estradiol  stimulation of HMG-CoA reductase was totally inhibited
;when sterol content was  elevated by aminoglutethimide, suggesting that
;estradiol stimulation of HMG-CoA  reductase expression is not sufficient to
;overcome the negative regulatory  effect of cholesterol.
;[2031..2040]:substance:"estradiol"
;[2057..2074]:substance:"HMG-CoA reductase"
;[2102..2108]:substance:"sterol"
;[2134..2151]:substance:"aminoglutethimide"
;[2169..2178]:substance:"estradiol"
;[2194..2212]:substance:"HMG-CoA  reductase"
;[2289..2300]:substance:"cholesterol"
(SENT
  (S
    (ADVP (RB:[2022..2029] However))
    (,:[2029..2030] ,)
    (NP-SBJ-1
      (NP (NN:[2031..2040] estradiol) (NN:[2042..2053] stimulation))
      (PP (IN:[2054..2056] of)
        (NP (NN:[2057..2064] HMG-CoA) (NN:[2065..2074] reductase))))
    (VP (VBD:[2075..2078] was)
      (ADVP (RB:[2079..2086] totally))
      (VP (VBN:[2087..2096] inhibited)
        (NP-1 (-NONE-:[2096..2096] *))
        (SBAR-ADV
          (WHADVP-3 (WRB:[2097..2101] when))
          (S
            (NP-SBJ-2 (NN:[2102..2108] sterol) (NN:[2109..2116] content))
            (VP (VBD:[2117..2120] was)
              (VP (VBN:[2122..2130] elevated)
                (NP-2 (-NONE-:[2130..2130] *))
                (PP (IN:[2131..2133] by)
                  (NP-LGS (NN:[2134..2151] aminoglutethimide)))
                (ADVP-TMP-3 (-NONE-:[2151..2151] *T*))))))
        (,:[2151..2152] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[2152..2152] *))
          (VP (VBG:[2153..2163] suggesting)
            (SBAR (IN:[2164..2168] that)
              (S
                (NP-SBJ-4
                  (NP (NN:[2169..2178] estradiol) (NN:[2179..2190] stimulation))
                  (PP (IN:[2191..2193] of)
                    (NP
                      (NML (NN:[2194..2201] HMG-CoA) (NN:[2203..2212] reductase))
                      (NN:[2213..2223] expression))))
                (VP (VBZ:[2224..2226] is)
                  (ADJP-PRD (RB:[2227..2230] not) (JJ:[2231..2241] sufficient)
                    (S
                      (NP-SBJ-4 (-NONE-:[2241..2241] *))
                      (VP (TO:[2242..2244] to)
                        (VP (VB:[2245..2253] overcome)
                          (NP
                            (NP (DT:[2254..2257] the) (JJ:[2258..2266] negative)
                                (JJ:[2267..2277] regulatory)
                                (NN:[2279..2285] effect))
                            (PP (IN:[2286..2288] of)
                              (NP (NN:[2289..2300] cholesterol)))))))))))))))
    (.:[2300..2301] .)))

;sentence 14 Span:2302..2572
;In contrast to HMG-CoA reductase mRNA which appears to be  controlled by
;sterol and estradiol, P-450scc mRNA levels remained constant in  corpora
;lutea despite wide changes in sterol and steroid content induced by  either
;4-APP, aminoglutethimide or estradiol treatment.
;[2317..2339]:substance:"HMG-CoA reductase mRNA"
;[2375..2381]:substance:"sterol"
;[2386..2395]:substance:"estradiol"
;[2397..2410]:substance:"P-450scc mRNA"
;[2478..2484]:substance:"sterol"
;[2489..2496]:substance:"steroid"
;[2524..2529]:substance:"4-APP"
;[2531..2548]:substance:"aminoglutethimide"
;[2552..2561]:substance:"estradiol"
(SENT
  (S
    (PP (IN:[2302..2304] In)
      (NP
        (NP (NN:[2305..2313] contrast))
        (PP (TO:[2314..2316] to)
          (NP
            (NP
              (NML (NN:[2317..2324] HMG-CoA) (NN:[2325..2334] reductase))
              (NN:[2335..2339] mRNA))
            (SBAR
              (WHNP-1 (WDT:[2340..2345] which))
              (S
                (NP-SBJ-1 (-NONE-:[2345..2345] *T*))
                (VP (VBZ:[2346..2353] appears)
                  (S
                    (NP-SBJ-1 (-NONE-:[2353..2353] *))
                    (VP (TO:[2354..2356] to)
                      (VP (VB:[2357..2359] be)
                        (VP (VBN:[2361..2371] controlled)
                          (NP-1 (-NONE-:[2371..2371] *))
                          (PP (IN:[2372..2374] by)
                            (NP-LGS (NN:[2375..2381] sterol)
                                    (CC:[2382..2385] and)
                                    (NN:[2386..2395] estradiol))))))))))))))
    (,:[2395..2396] ,)
    (NP-SBJ
       (NN:[2397..2405] P-450scc) (NN:[2406..2410] mRNA)
      (NNS:[2411..2417] levels))
    (VP (VBD:[2418..2426] remained)
      (ADJP-PRD (JJ:[2427..2435] constant))
      (PP-LOC (IN:[2436..2438] in)
        (NP (NNS:[2440..2447] corpora) (NNS:[2448..2453] lutea)))
      (PP (IN:[2454..2461] despite)
        (NP
          (NP
            (NP (JJ:[2462..2466] wide) (NNS:[2467..2474] changes))
            (PP (IN:[2475..2477] in)
              (NP
                (NP (NN:[2478..2484] sterol))
                (CC:[2485..2488] and)
                (NP (JJ:[2489..2496] steroid) (NN:[2497..2504] content)))))
          (VP (VBN:[2505..2512] induced)
            (NP (-NONE-:[2512..2512] *))
            (PP (IN:[2513..2515] by)
              (NP-LGS (CC:[2517..2523] either)
                (NP (NN:[2524..2529] 4-APP))
                (,:[2529..2530] ,)
                (NP (NN:[2531..2548] aminoglutethimide))
                (CC:[2549..2551] or)
                (NP (NN:[2552..2561] estradiol) (NN:[2562..2571] treatment))))))))
    (.:[2571..2572] .)))

;sentence 15 Span:2573..2672
;However, interestingly,  aminoglutethimide increased substantially the
;content of P-450scc protein.
;[2598..2615]:substance:"aminoglutethimide"
;[2655..2671]:cyp450:"P-450scc protein"
(SENT
  (S
    (ADVP (RB:[2573..2580] However))
    (,:[2580..2581] ,)
    (ADVP (RB:[2582..2595] interestingly))
    (,:[2595..2596] ,)
    (NP-SBJ (NN:[2598..2615] aminoglutethimide))
    (VP (VBD:[2616..2625] increased)
      (ADVP (RB:[2626..2639] substantially))
      (NP
        (NP (DT:[2640..2643] the) (NN:[2644..2651] content))
        (PP (IN:[2652..2654] of)
          (NP (NN:[2655..2663] P-450scc) (NN:[2664..2671] protein)))))
    (.:[2671..2672] .)))

;sentence 16 Span:2673..2913
;This  increase in P-450scc enzyme was not due to a greater amount of
;translatable  message since similar levels of immunoprecipitable 35S-P-450scc
;were translated  in vitro from luteal mRNA of rats treated with or without
;aminoglutethimide.
;[2691..2706]:cyp450:"P-450scc enzyme"
;[2807..2819]:substance:"35S-P-450scc"
;[2858..2862]:substance:"mRNA"
;[2895..2912]:substance:"aminoglutethimide"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2673..2677] This) (NN:[2679..2687] increase))
      (PP (IN:[2688..2690] in)
        (NP (NN:[2691..2699] P-450scc) (NN:[2700..2706] enzyme))))
    (VP (VBD:[2707..2710] was) (RB:[2711..2714] not)
      (PP-PRD (JJ:[2715..2718] due)
        (PP (TO:[2719..2721] to)
          (NP
            (NP (DT:[2722..2723] a) (JJR:[2724..2731] greater)
                (NN:[2732..2738] amount))
            (PP (IN:[2739..2741] of)
              (NP (JJ:[2742..2754] translatable) (NN:[2756..2763] message))))))
      (SBAR-ADV (IN:[2764..2769] since)
        (S
          (NP-SBJ-1
            (NP (JJ:[2770..2777] similar) (NNS:[2778..2784] levels))
            (PP (IN:[2785..2787] of)
              (NP (JJ:[2788..2806] immunoprecipitable)
                  (NN:[2807..2819] 35S-P-450scc))))
          (VP (VBD:[2820..2824] were)
            (VP (VBN:[2825..2835] translated)
              (NP-1 (-NONE-:[2835..2835] *))
              (ADVP (FW:[2837..2839] in) (FW:[2840..2845] vitro))
              (PP (IN:[2846..2850] from)
                (NP
                  (NP (JJ:[2851..2857] luteal) (NN:[2858..2862] mRNA))
                  (PP (IN:[2863..2865] of)
                    (NP
                      (NP (NNS:[2866..2870] rats))
                      (VP (VBN:[2871..2878] treated)
                        (NP (-NONE-:[2878..2878] *))
                        (PP-MNR (IN:[2879..2883] with) (CC:[2884..2886] or)
                                (IN:[2887..2894] without)
                          (NP (NN:[2895..2912] aminoglutethimide)))))))))))))
    (.:[2912..2913] .)))

;sentence 17 Span:2914..3110
;In  summary, results of this investigation have revealed that the expression
;of  HMG-CoA reductase and cytochrome P-450scc are controlled by totally
;different  mechanisms in the rat corpus luteum.
;[2995..3012]:substance:"HMG-CoA reductase"
;[3017..3036]:cyp450:"cytochrome P-450scc"
(SENT
  (S
    (PP (IN:[2914..2916] In)
      (NP (NN:[2918..2925] summary)))
    (,:[2925..2926] ,)
    (NP-SBJ
      (NP (NNS:[2927..2934] results))
      (PP (IN:[2935..2937] of)
        (NP (DT:[2938..2942] this) (NN:[2943..2956] investigation))))
    (VP (VBP:[2957..2961] have)
      (VP (VBN:[2962..2970] revealed)
        (SBAR (IN:[2971..2975] that)
          (S
            (NP-SBJ-1
              (NP (DT:[2976..2979] the) (NN:[2980..2990] expression))
              (PP (IN:[2991..2993] of)
                (NP
                  (NP (NN:[2995..3002] HMG-CoA) (NN:[3003..3012] reductase))
                  (CC:[3013..3016] and)
                  (NP (NN:[3017..3027] cytochrome) (NN:[3028..3036] P-450scc)))))
            (VP (VBP:[3037..3040] are)
              (VP (VBN:[3041..3051] controlled)
                (NP-1 (-NONE-:[3051..3051] *))
                (PP (IN:[3052..3054] by)
                  (NP-LGS (RB:[3055..3062] totally) (JJ:[3063..3072] different)
                          (NNS:[3074..3084] mechanisms)))
                (PP-LOC (IN:[3085..3087] in)
                  (NP (DT:[3088..3091] the) (NN:[3092..3095] rat)
                      (NN:[3096..3102] corpus) (NN:[3103..3109] luteum)))))))))
    (.:[3109..3110] .)))

;section 18 Span:3110..3143
;(ABSTRACT TRUNCATED AT 400 WORDS)
(SEC
  (FRAG (-LRB-:[3110..3111] -LRB-) (NN:[3111..3119] ABSTRACT)
        (VBN:[3120..3129] TRUNCATED) (IN:[3130..3132] AT) (CD:[3133..3136] 400)
        (NNS:[3137..3142] WORDS) (-RRB-:[3142..3143] -RRB-)))

;section 19 Span:3147..3191
;PMID: 2351103 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[3147..3151] PMID) (::[3151..3152] :) (CD:[3153..3160] 2351103)
        (NN:[3161..3162] -LSB-) (NNP:[3162..3168] PubMed) (::[3169..3170] -)
        (NN:[3171..3178] indexed) (IN:[3179..3182] for)
        (NNP:[3183..3191] MEDLINE-RSB-)))
